Strs Ohio increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 20.9% during the second quarter, according to its most recent filing with the SEC. The fund owned 15,551 shares of the medical equipment provider’s stock after buying an additional 2,686 shares during the period. Strs Ohio’s holdings in Zimmer Biomet Holdings were worth $1,996,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its position in Zimmer Biomet Holdings by 4,042.4% in the first quarter. BlackRock Inc. now owns 16,740,383 shares of the medical equipment provider’s stock worth $2,044,168,000 after buying an additional 16,336,262 shares during the period. Vanguard Group Inc. boosted its position in Zimmer Biomet Holdings by 3.7% in the first quarter. Vanguard Group Inc. now owns 13,041,411 shares of the medical equipment provider’s stock worth $1,592,488,000 after buying an additional 464,916 shares during the period. State Street Corp boosted its position in Zimmer Biomet Holdings by 2.4% in the first quarter. State Street Corp now owns 8,193,165 shares of the medical equipment provider’s stock worth $1,000,463,000 after buying an additional 191,747 shares during the period. Nordea Investment Management AB boosted its position in Zimmer Biomet Holdings by 25.0% in the first quarter. Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider’s stock worth $602,159,000 after buying an additional 987,398 shares during the period. Finally, First Manhattan Co. boosted its position in Zimmer Biomet Holdings by 13.5% in the first quarter. First Manhattan Co. now owns 2,565,370 shares of the medical equipment provider’s stock worth $333,549,000 after buying an additional 305,668 shares during the period. 83.62% of the stock is currently owned by institutional investors.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at 110.13 on Friday. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.49. The stock has a market cap of $22.22 billion, a price-to-earnings ratio of 31.37 and a beta of 1.20. The stock’s 50 day moving average is $125.44 and its 200 day moving average is $121.28.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.10 by $0.02. The firm had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The company’s quarterly revenue was up 1.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.02 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 annualized dividend and a dividend yield of 0.87%. Zimmer Biomet Holdings’s payout ratio is 27.59%.

TRADEMARK VIOLATION WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.watchlistnews.com/zimmer-biomet-holdings-inc-nysezbh-shares-bought-by-strs-ohio/1472079.html.

ZBH has been the topic of several recent research reports. Zacks Investment Research cut shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Thursday, April 13th. Canaccord Genuity reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a research report on Friday, April 28th. Royal Bank Of Canada raised their price target on shares of Zimmer Biomet Holdings from $133.00 to $140.00 and gave the company an “outperform” rating in a research report on Wednesday, June 21st. Bank of America Corporation reaffirmed a “buy” rating and issued a $158.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Finally, BidaskClub cut shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $137.76.

In other news, insider Sang Yi sold 17,731 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $124.56, for a total transaction of $2,208,573.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The disclosure for this sale can be found here. 1.07% of the stock is owned by insiders.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.